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AbstrAct
ObJEctIVE: the prevalence and clinical features of thyroid involvement in patients with 
hepatitis c virus-associated mixed cryoglobulinemia (Mc+HcV) have been reviewed. DEsIGN: 
A PubMed Medline search was conducted through December 2011 to identify all studies that 
reported thyroid involvement in Mc+HcV patients. reference lists of the papers initially de-
tected were manually searched to identify additional relevant reports. studies had to contain 
sufficient and clear information to be included. rEsULts: In Mc+HcV patients, the fol-
lowing thyroid autoimmune abnormalities were significantly more frequent than in controls: 
high levels of serum anti-thyroperoxidase autoantibody (AbtPO); high levels of serum AbtPO 
and/or anti-thyroglobulin autoantibody; humoral and ultrasonographical signs of thyroid 
autoimmunity (35% vs 16%); prevalence of subclinical hypothyroidism (11% vs 2%). Also, the 
prevalence of papillary thyroid cancer has been found higher in Mc+HcV patients than in 
controls, in particular in patients with autoimmune thyroiditis. the involvement of t helper 1 
immunity and chemokine (c-X-c motif) ligand 10 (cXcL10) may be the pathogenetic basis of 
the association between Mc+HcV and thyroid autoimmunity. cONcLUsION: these results 
show a high prevalence of thyroid disorders in patients with Mc+HcV and point to the need 
for careful monitoring of thyroid function in these patients.
Key words: Autoimmunity, Chemokines, Cryoglobulinemia, Hepatitis C, Hypothyroidism, Thy-
roid neoplasms
HORMONES 2014, 13(1):16-23
Address for correspondence:
Alessandro Antonelli, MD,  
Department of Clinical and Experimental Medicine, 
University of Pisa, Via Savi, 10, I-56126, Pisa, Italy,  
Tel.: +39-050-992318; Fax: +39-050-553235;
E-mail: alessandro.antonelli@med.unipi.it
Received 05-12-2012, Accepted 12-06-2013
Review
IntroductIon
Hepatitis C virus (HCV) is known to be responsible 
for both hepatic and extrahepatic diseases (HCV-
related extrahepatic diseases = HCV-EHDs). The 
most important systemic HCV-EHDs are HCV-
Thyroid involvement in cryoglobulinemia 17
related mixed cryoglobulinemia (MC+HCV) and 
lymphoproliferative disorders, while the most frequent 
and clinically important endocrine HCV-EHDs are 
thyroid disorders and type 2 diabetes mellitus (T2D). 
To the best of our knowledge, no study has re-
viewed thyroid disorders in cryoglobulinemia. Here, 
a review of the literature about the association of 
MC+HCV and thyroid disorders is reported. A 
PubMed Medline search was conducted through 
December 2011 to identify all studies that reported 
thyroid involvement in MC+HCV patients. Reference 
lists of the papers initially detected were manually 
searched to identify additional relevant reports. Stud-
ies had to contain sufficient and clear information to 
be included.
Thyroid autoimmunity and HCV
Several studies have been conducted to evaluate 
the real prevalence of thyroid autoimmunity (AT) 
in HCV positive (HCV+) patients, these however 
reporting conflicting results (Table 1). From a meta-
analysis of the literature, a significant association 
between HCV infection and AT and/or dysfunction 
has been reported.1-3
A large study investigated the prevalence of thyroid 
disorders in 630 consecutive patients with chronic 
hepatitis due to HCV infection (CHC) not treated 
with interferon (IFN)-α as compared with a control 
group of 389 subjects from an iodine-deficient area, 
another control group of 268 persons living in an area 
of iodine sufficiency and 86 patients with chronic hepa-
titis B. Patients with CHC were more likely to have 
hypothyroidism (13%), anti-thyroglobulin antibodies 
(AbTg) (17%) and anti-thyroperoxidase antibodies 
(AbTPO) (21%) than were any of the other groups.4 
These results have recently been confirmed in a 
retrospective cohort study of users of the US Veter-
ans Affairs health care facilities from 1997 to 2004, 
which included 146,394 HCV+ patients and 572,293 
patients uninfected with HCV. The thyroiditis risk 
was significantly increased in HCV+ patients. This 
result is particularly interesting since 97% of HCV+ 
patients were men and it is well known that male 
gender implies a lower risk of thyroiditis than female 
gender.5
Thyroid disorders observed in HCV chronic in-
fection2,4 are associated with a higher risk of AT 
in the female gender and furthermore there is an 
increased risk of hypothyroidism in female AbTPO 
positive subjects.
Thyroid dysfunctions (TD) in MC+HCV
Few studies have evaluated autoimmune thyroid 
disorders (AITD) in patients with cryoglobulinemia 
(Table 2). In a study by Codes et al,6 127 patients with 
positive anti-HCV results were evaluated, based on 
detectable ribonucleic acid (RNA)-HCV by reverse 
transcriptase-polymerase chain reaction (RT-PCR) 
of genotypes 1a, 1b and 3a. TD occurred in 7/30 
(23.3%) of the patients infected by genotype 3 (p = 
table 1. Papers that evaluated the interrelationship between HCV infection and AT
Field of interest Author Main findings
Association between 
HCV infection and 
AT/or dysfunction
Pateron et al1 Increase of latent autoimmune thyroid diseases in patients with chronic hepatitis C
Antonelli et al2 Significant increase of the prevalence has been observed both for thyroid autoimmune disorders 
(OR= 1.6, 95% confidence interval 1.4-1.9) as well as for hypothyroidism (OR= 2.9; confi-
dence interval 2-4.1) in HCV-positive patients (with chronic hepatitis or HCVAb positivity)
Antonelli et al3 Significant associations among chronic HCV infection, thyroid autoimmunity and hypothy-
roidism have been revealed. A high prevalence of thyroid cancer has been reported in HCV-
positive patients. Chronic HCV infection could lead to the development of type 2 diabetes 
mellitus, possibly as a result of HCV-induced metabolic disturbances
Antonelli et al4 Patients with CHC were more likely to have hypothyroidism (13%), AbTg (17%) and AbTPO 
(21%) than were controls
Giordano et al5 Thyroiditis risk is significantly increased in male HCV+ with respect to uninfected patients
AbTg: anti-thyroglobulin antibody, AbTPO: anti-thyroperoxidase antibody, AT: thyroid autoimmunity, HCV: hepatitis C virus, CHC: 
patients with chronic hepatitis due to HCV infection, OR: odds ratio.
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table 2. Papers that evaluated the interrelationship among HCV infection, MC, TD and AITD
Field of interest Author Main findings
Association between  
HCV infection  
and development  
of TD and AITD
Giordano et al5 Thyroiditis risk is significantly increased in male HCV+ in comparison with 
uninfected patients
Antonelli et al15 Higher prevalence of TSH, AbTg and AbTPO levels, and hypothyroidism in 
HCV+ patients (p <0.001 for all)
Association between 
MC+HCV and 
development of TD  
and AITD
Codes et al6 HCV+ patients, genotype 3, develop TD with a prevalence rate of 23.3% (p = 
0.05) and MC in 38% of cases (p = 0.02)
Zarebska-Michaluk et al7 HCV+ patients develop AITD with a prevalence rate of 16.2%, and MC in 37.1%
Castellano et al9 Case report of hypothyroidism, hemolytic anemia and cryoglobulinemia in a 
patient with HCV infection
Antonelli et al10 Higher prevalence of AITD in patients with MC+HCV, not only with respect to 
controls (AbTPO 28% vs 9%, p = 0.001; AbTPO and/or AbTg 31% vs 12%, p = 
0.004; thyroid autoimmunity 35% vs 16%, p = 0.006; subclinical hypothyroidism 
11% vs 2%, p = 0.038), but also with respect to HCV+ patients without 
cryoglobulinemia (AbTPO 28% vs 14%, p = 0.035)
AbTg: anti-thyroglobulin antibody, AbTPO: anti-thyroperoxidase antibody, AITD: autoimmune thyroid disorders, HCV: hepatitis C 
virus, HCV+: HCV positive patients, MC: mixed cryoglobulinemia, MC+HCV: HCV-related MC, TD: thyroid dysfunctions, TSH: 
thyroid-stimulating hormone.
0.05) and cryoglobulinemia was also more frequent 
in this group (5/13, 38%, p = 0.02). 
Zarebska-Michaluk et al7 studied 340 consecutive 
patients (mean age: 42 years) with untreated CHC to 
assess the prevalence and predictive factors of extra-
hepatic manifestation (EM) in Poland. Two hundred 
ten patients with CHC (61.7%) presented at least 
one EM, including MC (37.1%), thrombocytopenia 
(27.6%), AT (16.2%), dermatological disorders (4.1%) 
and T2D (4.1%). The authors conclude that in Poland 
the majority of patients with CHC have EM in con-
junction with cryoglobulinemia, thrombocytopenia, 
AT, dermatological disorders and T2D.
Furthermore, anecdotal studies have reported 
TD in MC+HCV patients. For example, a case of 
hyperthyroidism due to the presence of “thyroid-
stimulating immunoglobulins” and Graves’ disease 
in a patient with MC (type II) was reported,8 while 
Castellano et al9 described a case of hypothyroidism, 
hemolytic anemia and cryoglobulinemia in a patient 
with HCV infection.
More recently, a case-control prospective study 
was conducted: 93 MC+HCV patients were matched 
by gender and age (+/- 2 years) to 93 patients with 
CHC without MC and 93 healthy (HCV-negative) 
controls from the local population. Serum AbTPO 
(28% vs 9%), serum AbTPO and/or AbTg (31% vs 
12%), AT (35% vs 16%) and subclinical hypothyroid-
ism (11% vs 2%) were significantly more frequent in 
MC+HCV patients than in HCV-negative controls. 
Serum AbTPO were also significantly more frequent 
in MC+HCV patients than in CHC controls (28% 
vs 14%). These results showed a higher prevalence 
of thyroid disorders in patients with MC+HCV in 
comparison with controls and with HCV+ patients 
without cryoglobulinemia.10
Thyroid disorders observed in MC+HCV infec-
tion2,4 are associated with a higher risk of AT in the 
female gender and furthermore there is an increased 
risk of hypothyroidism in female AbTPO positive 
subjects (similarly to HCV+ patients without MC).
Thyroid cancer (TC)
A high prevalence of papillary thyroid cancer (PTC; 
Table 3) was first observed over a decade ago in 139 
HCV+ patients (2.2%), while no case was observed 
in 835 control subjects, long-term residents of an 
iodine-deficient area.11
Subsequently, a case-control study reported that 
in patients undergoing surgery for PTC, the pres-
ence of HCV infection was significantly higher than 
in subjects undergoing surgery for benign disorders, 
particularly in women.12 
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More recently, 459 patients were screened with 
different types of cancer: 130 TC, 114 liver cancer, 
41 multiple myeloma, 111 non-Hodgkin’s lymphoma, 
63 Hodgkin’s disease, in comparison with a control 
group of 226 patients with no history of cancer.13 Liver 
cancer [odds ratio (OR) 32.9, 95% confidence interval 
(95% CI) 16.5-65.4, p < 0.0001], multiple myeloma 
(OR 4.5, 95% CI 1.9-10.7, p = 0.0004) and B-cell non-
Hodgkin’s lymphoma (OR 3.7, 95% CI 1.9-7.4, p = 
0.0001) showed greater risks. For Hodgkin’s disease 
there was no significant association (p = 0.3), while a 
link was noted between HCV and TC (OR 2.8, 95% 
CI 1.2-6.3, p = 0.01). 
However, the above reported retrospective cohort 
study of users of the US Veterans Affairs health care 
facilities did not confirm an increased risk of TC in 
HCV+ patients. This result is interesting; however, 
since 97% of HCV+ patients were men and male 
gender implies a lower risk of TC than female gender, 
it needs to be regarded with caution.5
A prospective study investigated prevalence and 
features of TC in 308 patients with CHC vs two gen-
der- and age-matched control groups: 616 subjects 
from an iodine-deficient area and 616 subjects from 
an iodine-sufficient area. Among HCV+ patients, 6 
patients with PTC were detected, while no case was 
observed in control 1 (p = 0.001) and only one case 
in control 2 (p = 0.003). In HCV+ patients, 83% with 
TC had evidence of AT vs 31% of the other HCV+ 
patients (p = 0.02).14
The prevalence of TC was also investigated in a 
series of 94 unselected MC+HCV patients in com-
parison with a gender- and age-matched control group 
obtained from a sample of the general population 
(470 subjects). The prevalence of thyroid nodules 
was higher in control subjects than in MC patients 
(65.3% vs 54.8%), albeit not significantly. In the MC 
series, two patients with PTC were found, while no 
case was observed among controls (p = 0.001, χ2 P 
value); lymphocytic infiltration was observed in the 
thyroid tissue in both MC patients with PTC.15
Recently, other studies have confirmed an asso-
ciation between AT and TC.16 Accordingly, features 
of AT were observed more frequently in HCV+ 
patients than in controls, suggesting that AT may 
be a predisposing condition for TC.14 The finding of 
an increased prevalence of TC in HCV+ patients is 
clinically relevant since about 15-30% of these patients 
may show an aggressive disease difficult to treat.17 
Of interest, thyroid autoimmunity and chronic 
thyroiditis have been regarded as preneoplastic con-
ditions. Okayasu et al18 found that the prevalence 
of lymphocytic infiltrates, which are indicative of 
autoimmune thyroiditis, was significantly higher in 
patients with PTC than in patients with adenomatous 
goiter or follicular adenoma.
table 3. Papers that evaluated the interrelationship among HCV infection, MC and thyroid cancer
Field of interest Author Main findings
Association between 
HCV and development 
of thyroid cancer 
Antonelli et al11 HCV+ patients develop papillary thyroid cancer with a prevalence rate of 2.2% vs 0% 
among controls
Montella et al12 In patients undergoing surgery for papillary thyroid cancer, the presence of HCV infection 
is significantly higher than that observed in subjects undergoing surgery for benign 
disorders, particularly in women
Montella et al13 An association between thyroid cancer and HCV infection is noted with OR 2.8, 95% 
CI 1.2-6.3, p = 0.01
Giordano et al5 No association
Antonelli et al14 Higher prevalence of papillary thyroid cancer in HCV+ patients, in particular in the 
presence of thyroid autoimmunity
Association between 
MC+HCV and 
development of thyroid 
cancer
Antonelli et al15 Higher prevalence of papillary thyroid cancer in MC patients vs controls (p = 0.001, c2 
P value; p = 0.02, Fisher’s exact test). In MC patients with papillary thyroid cancer there 
is evidence of lymphocytic infiltration in the thyroid tissue
95% CI: 95% confidence interval, HCV: hepatitis C virus, HCV+: HCV positive patients, MC: mixed cryoglobulinemia, MC+HCV: 
HCV-related MC, OR: odds ratio.
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These findings have recently been confirmed in a 
study that found patients with a high titer of thyroid 
autoantibodies showed a higher frequency of PTC 
(9.3%) compared to patients with a low titer or 
negative thyroid autoantibodies (about 6.5%) and 
also presented higher serum TSH (median 1.16 vs 
0.75 μU/ml).16
In our HCV-related mixed cryoglobulinemia pa-
tient series both patients with PTC had lymphocytic 
infiltration of the thyroid.15 Features of thyroid auto-
immunity were observed more frequently in HCV+ 
patients than in controls, indicating that thyroid 
autoimmunity may be a predisposing condition for 
thyroid papillary cancer.15
An oncogenic role for HCV has been demonstrated 
in the case of hepatocellular carcinoma complicating 
chronic HCV infection, with or without cirrhosis as an 
intermediate.19 As HCV is an RNA virus that cannot 
be integrated in the host genome, its oncogenic poten-
tial must be exerted through indirect mechanisms.19
What mechanisms transduce the HCV oncogenic 
potential in TC remain to be investigated; however, the 
association between TC and AT in MC+HCV patients 
points to a possible link between these disorders.
IFN-α in MC
IFN-α therapy for hepatitis C is associated with a 
high prevalence of TD. IFN-α is the main therapeu-
tic agent for patients with CHC. Studies show that 
2.5-20% of patients with CHC develop TD while on 
IFN-α therapy.20 Although the etiology is not clear, 
research suggests that IFN-α induces an autoimmune 
reaction that leads to the development of anti-thyroid 
antibodies and subsequent TD.20 The frequency of 
pre-treatment thyroid disorders, the induction of 
thyroid antibodies and the development of TD during 
IFN-α therapy are all reduced in patients with chronic 
hepatitis B compared with patients with CHC.4,20 This 
finding implies that prevalence of thyroid disorders 
in IFN-α treated patients with CHC is due not only 
to the effect of the drug per se, but to the action of 
the drug on an immunological background that is 
predisposed to the development of TD, such as the 
predisposition to AT in HCV+ patients. 
Thyroid disorders associated with IFN-α therapy 
include hypothyroidism (the most common), autoim-
mune primary hypothyroidism, Graves’ hyperthyroid-
ism and destructive thyroiditis.
TD resolves within 6 months of ending treatment 
in ~50% of patients; however, persistent TD requires 
specific treatment for hypothyroidism or Graves’ hy-
perthyroidism. Regular follow-up tests should also be 
performed at 3-6 month intervals during treatment. 
A recent paper has further evaluated the effect on 
IFN-α therapy on the thyroid in patients with CHC.21
No study has as yet evaluated prospectively the 
effect of IFN-α on thyroid function in patients with 
MC+HCV and only anecdotal reports are available 
in the literature.
Papo et al22 reported the case of a 40-year-old 
woman treated with IFN-α for the management 
of essential cryoglobulinemia. Goiter enlargement 
was noticed after one year of IFN-α therapy. Free 
triiodothyronine and free thyroxine serum values, 
measured by radioimmunoassay, were apparently 
elevated, thus contrasting with clinical euthyroidism 
and normal thyroid-stimulating hormone (TSH) 
values. High serum levels of antithyroid hormone 
antibodies were found in the patients’ serum via a 
radiolabeled hormone immunoprecipitation assay. 
AbTg and AbTPO titers were also elevated and paral-
leled antithyroid hormone antibodies. Clinical status 
and TSH levels remained normal after cessation of 
IFN-α therapy, while thyroid hormones values and 
anti-thyroid hormone antibody levels progressively 
normalized. This was the first report of anti-thyroid 
hormone antibodies induced by IFN-α. 
Mazzaro et al23 reported two patients treated with 
alpha 2b-IFN who developed hypothyroidism.
Since MC+HCV patients have a higher preva-
lence of AT than HCV+ patients without MC, and 
consequently MC+HCV are more prone to the de-
velopment of TD during IFN-α therapy, prospective 
studies in the field are needed.
Pathogenesis
The pattern of thyroid disorders observed in HCV 
infection is characterized by the presence of increased 
circulating levels of AbTPO and increased risk of hy-
pothyroidism in AbTPO positive subjects.2 This pattern 
is similar to that observed in IFN-α treated patients 
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too.24 An increased expression of interferon-gamma 
(IFN-γ), and IFN-γ inducible chemokines,25 especially 
chemokine (C-X-C motif) ligand 10 (CXCL10), has 
been shown in hepatocytes and in lymphocytes of 
HCV infected patients, directly related to the degree 
of inflammation and with an increase of IFN-γ and 
CXCL10 circulating levels.24
Moreover, non-structural 5A protein and core 
proteins, alone or acting via the synergistic effect of 
cytokines, such as IFN-γ and tumor necrosis factor-
alpha (TNF-α), are able to upregulate CXCL10 
and CXCL9 gene expression and secretion in cul-
tured human hepatocyte-derived cells.26 Therefore, 
CXCL10-produced HCV-infected hepatocytes could 
play a key role in regulating T-cell trafficking into a 
T helper (Th) 1-type inflammatory site, such as the 
liver during chronic HCV infection, recruiting Th1 
lymphocytes.27-29 It has been shown that high CXCL10 
levels are present in patients with AT, especially in 
the presence of hypothyroidism, and an involvement 
of Th1 immune response in the induction of AT,30 
Graves’ disease and Graves’ ophthalmopathy has 
been demonstrated.27-29 Furthermore, the presence 
of HCV in the thyroid of chronically infected patients 
has been documented.31,32
In order to explore HCV-thyroid interactions at 
a cellular level, it was evaluated whether a human 
thyroid cell line (ML1, that shows robust surface 
expression of the major HCV receptor CD81) could 
be infected with HCV in vitro. It was demonstrated 
that HCV can infect human thyroid cells in vitro, 
suggesting that HCV infection of thyrocytes may 
play a role in the association between chronic HCV 
infection and thyroid autoimmunity.33 
In agreement with the aforementioned, it could 
be speculated that HCV thyroid infection acts by 
upregulating CXCL10 gene expression and secretion 
in thyrocytes, recruiting Th1 lymphocytes, that secrete 
IFN-γ and TNF-α, which further induce CXCL10 
secretion by thyrocytes, in this way perpetuating the 
immune cascade that leads to the appearance of 
AITD in genetically predisposed subjects.
This hypothesis has been confirmed by one study 
that evaluated serum levels of CXCL10, and of the pro-
totype Th2 chemokine (C-C motif) ligand 2 (CCL2), 
in MC patients, and showed that CXCL10, but not 
CCL2, is significantly higher in the presence of AT, 
vs patients without thyroiditis. These findings indi-
cate that the Th1 CXCL10 chemokine is specifically 
linked with the appearance of AT in these patients.34
CXCL10 and CCL2 serum levels were assayed in 
60 patients with MC, in 45 patients with “MC with 
AT” (MC+AT) and in controls [60 without (called 
“control 1”) and 45 with (called “control 2”) AT]. 
CXCL10 was significantly higher in control 2 than 
in control 1 (p <0.001) and in MC than in control 1. 
Moreover, CXCL10 chemokine levels were higher in 
MC+AT than in controls 1 and 2 and in MC (p = 
0.002). A high CXCL10 level (> mean ± Standard 
Deviation [SD] control 1; >167 pg/mL) was present 
in 7% control 1, 21% control 2, 49% MC and 78% 
MC+AT (p <0.0001). CCL2 serum levels were sig-
nificantly higher in MC and in MC+AT than in 
control 1 or in control 2 (p <0.01). A high CCL2 
level (> mean ± SD control 1; >730 pg/mL) was 
present in 2% control 1, 1% control 2, 18% MC and 
21% MC+AT (p <0.0001).34
Among the proinflammatory cytokines, in 
MC+HCV patients interleukin (IL)1-β and TNF-α 
were not associated with the presence of AT, while 
IL-6 was slightly but significantly increased in AT 
patients.35-37
On the whole, the abovementioned data underline 
the importance of the activation of Th1 immunity 
in the immunopathogenesis of AT in patients with 
MC+HCV.
conclusIon
A high prevalence of AITD and hypothyroidism 
has been shown in HCV chronic infection. MC+HCV 
patients have a higher prevalence of both AITD and 
TD than HCV+ patients without cryoglobulinemia. 
Female gender is a risk factor for the development 
of AT in MC+HCV patients, while risk factors for 
hypothyroidism are female gender and the pres-
ence of circulating AbTPO. These data suggest that 
MC+HCV patients, in particular in the case of female 
patients, should be screened for TSH and AbTPO 
at the first evaluation. A careful follow-up of thyroid 
function by annual TSH determination in female 
MC+HCV patients in the presence of circulating 
AbTPO should be conducted.
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IFN-α therapy is a well known risk for the develop-
ment of AT and dysfunctions in HCV+ patients. As 
MC+HCV patients have a higher prevalence of AT 
than HCV+ patients without MC, and consequently 
MC+HCV are more prone to the development of 
TD during IFN-α therapy, prospective studies in the 
field are needed. However, TSH and AbTPO should 
be evaluated before the start of IFN-α therapy, and 
at least every three months during IFN-α administra-
tion. In patients who develop a thyroid dysfunction, 
the appropriate therapy should be administered and 
thyroid function should be monitored at least every 
three months during the first year after the end of 
IFN-α. 
While other studies are needed to definitely con-
firm the association between TC and MC+HCV, 
the data available in the literature are sufficient to 
point to the need for careful thyroid monitoring by 
ultrasonography in these patients at the first evalua-
tion. In female patients, in particular in the presence 
of AT, thyroid ultrasonography could be repeated 
every two years.
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